Literature DB >> 9730422

Heart transplant coronary artery disease detected by coronary angiography: a multiinstitutional study of preoperative donor and recipient risk factors. Cardiac Transplant Research Database.

M R Costanzo1, D C Naftel, M R Pritzker, J K Heilman, J P Boehmer, S C Brozena, G W Dec, H O Ventura, J K Kirklin, R C Bourge, L W Miller.   

Abstract

BACKGROUND: Controversy exists regarding donor and recipient factors that promote the development and progression of coronary artery disease after heart transplantation and the likelihood of coronary artery disease causing death or retransplantation.
METHODS: To investigate this issue in a large cohort of patients, we analyzed 5963 postoperative angiograms performed in 2609 of the 3837 patients undergoing heart transplantation at 39 institutions between January 1990 and December 1994. Coronary artery disease was classified as mild, moderate, or severe on the basis of left main involvement, primary vessel stenoses, and branch stenoses. Coronary artery disease was considered severe if left main stenosis was > 70% or 2 or more primary vessels stenoses were > 70% or branch stenoses were > 70% in all 3 systems.
RESULTS: By the end of 5 years after heart transplantation, coronary artery disease was present in 42% of the patients, mild in 27%, moderate in 8%, and severe in 7%. Coronary artery disease-related events (death or retransplantation) had an actuarial incidence of 7% at 5 years and occurred in 2 of 3 of the patients with development of angiographically severe coronary artery disease. By multivariable logistic analysis, risk factors for donor coronary artery disease included older donor age (P < .0001) and donor hypertension (P=.0002). By multivariable analysis in the hazard function domain, risk factors identified for the earlier onset of allograft coronary artery disease included older donor age (P < .0001 ), donor male sex (P=.0006), donor hypertension (P=.07), recipient male sex (P=.02), and recipient black race (P=.01). The actuarial incidence of severe coronary artery disease was 9% at 5 years.
CONCLUSIONS: Angiographic coronary artery disease is very common after heart transplantation, occurring in approximately 42% of the patients by 5 years. Older donor age, donor hypertension, and male donor or recipient predict earlier onset of angiographic allograft coronary artery disease. Although severe angiographic allograft coronary artery disease occurs in only 7% of the patients at 5 years, its presence is highly predictive of subsequent coronary artery disease-related events or retransplantation.

Entities:  

Mesh:

Year:  1998        PMID: 9730422

Source DB:  PubMed          Journal:  J Heart Lung Transplant        ISSN: 1053-2498            Impact factor:   10.247


  47 in total

1.  Viral epidemiologic shift in inflammatory heart disease: the increasing involvement of parvovirus B19 in the myocardium of pediatric cardiac transplant patients.

Authors:  John P Breinholt; Mousumi Moulik; William J Dreyer; Susan W Denfield; Jeffrey J Kim; John L Jefferies; Joseph W Rossano; Corey M Gates; Sarah K Clunie; Karla R Bowles; Debra L Kearney; Neil E Bowles; Jeffrey A Towbin
Journal:  J Heart Lung Transplant       Date:  2010-04-24       Impact factor: 10.247

Review 2.  Pharmacotherapy of hyperlipidemia in pediatric heart transplant recipients: current practice and future directions.

Authors:  Clifford Chin; Daniel Bernstein
Journal:  Paediatr Drugs       Date:  2005       Impact factor: 3.022

3.  Viral endomyocardial infection is an independent predictor and potentially treatable risk factor for graft loss and coronary vasculopathy in pediatric cardiac transplant recipients.

Authors:  Mousumi Moulik; John P Breinholt; William J Dreyer; Debra L Kearney; Jack F Price; Sarah K Clunie; Brady S Moffett; Jeffrey J Kim; Joseph W Rossano; John Lynn Jefferies; Karla R Bowles; E O'Brian Smith; Neil E Bowles; Susan W Denfield; Jeffrey A Towbin
Journal:  J Am Coll Cardiol       Date:  2010-08-10       Impact factor: 24.094

Review 4.  Heart transplantation: approaching a new century.

Authors:  B Radovancević; O H Frazier
Journal:  Tex Heart Inst J       Date:  1999

Review 5.  Cardiac allograft vasculopathy: a review.

Authors:  Danny Ramzy; Vivek Rao; Julie Brahm; Santiago Miriuka; Diego Delgado; Heather J Ross
Journal:  Can J Surg       Date:  2005-08       Impact factor: 2.089

6.  Noninvasive PET quantitative myocardial blood flow with regadenoson for assessing cardiac allograft vasculopathy in orthotopic heart transplantation patients.

Authors:  Miguel Hernandez Pampaloni; Uttam M Shrestha; Maria Sciammarella; Youngho Seo; Grant T Gullberg; Elias H Botvinick
Journal:  J Nucl Cardiol       Date:  2017-01-30       Impact factor: 5.952

7.  Donor-specific antibodies to class II antigens are associated with accelerated cardiac allograft vasculopathy: a three-dimensional volumetric intravascular ultrasound study.

Authors:  Yan Topilsky; Manish J Gandhi; Tal Hasin; Laurie L Voit; Eugenia Raichlin; Barry A Boilson; John A Schirger; Brooks S Edwards; Alfredo L Clavell; Richard J Rodeheffer; Robert P Frantz; Sudhir S Kushwaha; Amir Lerman; Naveen L Pereira
Journal:  Transplantation       Date:  2013-01-27       Impact factor: 4.939

Review 8.  Cardiac allograft vasculopathy and insulin resistance--hope for new therapeutic targets.

Authors:  Luciano Potena; Hannah A Valantine
Journal:  Endocrinol Metab Clin North Am       Date:  2007-12       Impact factor: 4.741

9.  Multicenter assessment of coronary allograft vasculopathy by intravascular ultrasound-derived analysis of plaque composition.

Authors:  Giovanna Sarno; Amir Lerman; Jang-Ho Bae; Christoph Schukro; Dietmar Glogar; Pauliina M Margolis; Marc Goethals; Sofie Verstreken; Jozef Bartunek; Andreas Koenig; William Wijns; Marc Vanderheyden
Journal:  Nat Clin Pract Cardiovasc Med       Date:  2008-12-02

10.  The challenge to detect heart transplant rejection and transplant vasculopathy non-invasively - a pilot study.

Authors:  Engin Usta; Christof Burgstahler; Hermann Aebert; Stephen Schroeder; Uwe Helber; Andreas F Kopp; Gerhard Ziemer
Journal:  J Cardiothorac Surg       Date:  2009-08-16       Impact factor: 1.637

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.